µ²ºc¦¡ |
|
IdarucizumabÄÝ©ó¤@ºØdabigatranªº±M¤@©Ê¤ÏÂà§@¥Î¾¯¡C¸Óª«½è¬°¤HÃþ¤Æ³æ®è§ÜÅé¤ù¬q (Fab)¡A¹ïdabigatranªº¿Ë©M¤O·¥°ª¡A¬ù¤ñdabigatran¹ï¾®¦å酶ªºµ²¦X¤O±j¤W300¿¡C
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Idarucizumab-dabigatran½Æ¦XÅé¯S©Ê¬°¨³³tµ²¦X¦ý¤À¸Ñ·¥¬°½wºC¡A¥Nªí¸Ó½Æ¦XÅé·¥¬°Ã©w¡CIdarucizumab»Pdabigatran¤Î¨ä¥NÁª«¶i¦æ±j¤O¡B¨ã±M¤@©Êªºµ²¦X¡A¨Ã¤¤©M¨ä§Ü¾®¦å§@¥Î¡C
|
¾AÀ³¯g |
|
PraxbindÄÝ©ó¤@ºØ±M¤@©Êªºdabigatran¤ÏÂà§@¥Î¾¯¡A¾A¥Î©ó±µ¨ü´¶®ê¹F (Pradaxa) ªvÀø¡B»Ýn§Ö³t¤ÏÂàdabigatran§Ü¾®¦å§@¥Îªº¯f¤H¡GƒÜ ¨Ñºò«æ¤â³N¡þºò«æµ{§Ç¨Ï¥Î¡C ©ó«Â¯Ù¥Í©R©Î±±¨î¤£¨}ªº¥X¦å®É¨Ï¥Î¡C
|
¥Îªk¥Î¶q |
|
Praxbind«Øij¾¯¶q¬°5 g¡C ¨â50 ml¸Ë¤p²~(2 x 2.5 g)¤èº¡¨¬¤@¦¸§¹¾ã¾¯¶q¡C §¹¾ãªº5 g¾¯¶qÀ³¥HÀR¯ßª`®g¤è¦¡¬I¥Î¡A¤À¦¨¨â¦¸¦U©ó5-10¤ÀÄÁ¤º§¹¦¨³sÄò¿éª`¡A©Î¬O¤@¦¸ª`®g§¹²¦¡C
|
ÃİʤO¾Ç |
|
¤À¥¬ Idarucizumabªº°Ê¤O¾Ç«¬ºA¬°¤G«ÇÅé¤À¥¬¡C¸gÀR¯ß¿éª`5 g«á¡AéwºA¤À¥¬®e¿n (Vss)¤§´X¦ó¥§¡È¬°8.9 L¡]´X¦óÅܲ§«Y¼Æ [gCV] ¬°24.8%¡^¡C¦b¥½´Á®É¡A¤À¥¬®e¿n (Vz) ¬°41.8 L¡]gCV¬°22.3%¡^¡C ¥Íª«Âà´« ¥Ø«e¤w´£¥X¦hÓ»P§ÜÅé¥NÁ¦³Ãöªº³~®|¡C³o¨Ç³~®|³£²o¯AÂǥѥͪ«°¸Ñ§@¥Î¨Ï§ÜÅ馨¬°¸û¤p¤À¤l¡]§Y¤p«¬肽©ÎÓi°ò»Ä¡^¡A¦Ó³o¨Ç¸û¤p¤À¤l·|¦A§l¦¬¨Ã«·s¥Î©ó³J¥Õ½è¦X¦¨§@¥Î¡C ±Æ°£ Idarucizumab¥i§Ö³t±Æ°£¡A¨äÁ`²M°£²v¬°¨C¤ÀÄÁ47.0 mL (gCV 18.4%)¡Bªì©l¥b°I´Á¬°47¤ÀÄÁ (gCV 11.4%)¡A¥B²×ºÝ¥b°I´Á¬°10.3¤p®É (gCV 18.9%)¡C¸gÀR¯ß³~®|¬I¥Î5 g idarucizumab«á¡A32.1% (gCV 60.0%) ¦b6¤p®É¤º§Y±Æ¥X¡A©¹«á18¤p®É«h¤Ö©ó1%¡C©Ò¬I¥Î¾¯¶qªº³Ñ¾l³¡¤ÀÀ³°²©w¬°³z¹L³J¥Õ½è¦P¤Æ§@¥Î±Æ°£¡A¦Ó¸Ó§@¥Î¥Dn¦bµÇŦ¤º¶i¦æ¡C
|
°Æ§@¥Î |
|
¨Ã¥¼Æ[¹î¨ì¤£¨}¤ÏÀ³¡C
|
¥æ¤¬§@¥Î |
|
¥Ø«e©|¥¼¹ï Praxbind ©M¨ä¥LÃÄ«~¶i¦æ¥¿¦¡¥æ¤¬§@¥Î¸ÕÅç¡C ¨Ì¾Ú¥»ÃÄ«~ÃĪ«°Ê¤O¾Ç©Ê½è¤Î¹ï dabigatran °ª«×µ²¦X±M¤@©Ê¡AÀ³¤£P»P¨ä¥LÃÄ«~²£¥Í¨ãÁ{§É·N¸q¤§¥æ¤¬§@¥Î¡CÁ{§É«e¬ã¨sÅã¥Ü¥»ÃÄ«~¤£·|©M®e¿nÂX±i¾¯¡B¾®¦å¦]¤l¿@ÁY¾¯¤Î dabigatran ¥H¥~¤§§Ü¾®¦å¾¯²£¥Í¥æ¤¬§@¥Î¡C
|
¸T§Ò |
|
µL¡C
|
ª`·N¨Æ¶µ |
|
Idarucizumab ·|»Pdabigatran µo¥Í±M¤@©Êµ²¦X¡A¤ÏÂà¨ä§Ü¾®¦å§@¥Î¡A¦ý¤£·|¤ÏÂà¨ä¥L§Ü¾®¦å¾¯ªº§@¥Î¡C Praxbind ªvÀø¥i·f°tÂåÀø¤W¤¹³\ªº¼Ð·Ç¤ä´©©Ê±¹¬I¨Ï¥Î¡C
|
¹L¶q³B²z |
|
¥Ø«e¨ÃµL Praxbind ¥ÎÃĹL¶q¤§Á{§É¸gÅç¡C¹L¥h¥H°·±d¨ü¸ÕªÌ¶i¦æ¬ã¨s¤§³Ì°ª¾¯¶q¬° 8 g¡A¦Ó¸Ó¬ã¨s²Õ¨Ã¥¼¥X²{¦w¥þĵ°T¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
¨Ï¥Î«e±N¥¼¶}«ÊªºÃÄÅø«O¦s¦b«Ç·Å(25¢J)¤U¡A©óì¥]¸Ë¤º«O¦s¨ÃÁקK¥ú·Ó¡A³Ìªø¥i«O¦s48¤p®É¡F ¤w·Ó¥ú«h³Ìªø¥u¥i«O¦s6¤p®É¡C ÃÄ«~¦ÛÃIJ~©â¥X«á¡A¦b«Ç·Å¤Uªºª«¤Æ©Ê½èéw®É¶¡¬°1¤p®É¡C
|